中国全磁悬浮左心室辅助装置CH-VAD治疗晚期心衰的长期结局
该研究回顾性分析了阜外医院2017年6月至2023年8月连续50例植入CH-VAD的晚期心衰患者,平均支持868±630天,1年、2年和3年生存率分别为93%、93%和89%,主要不良事件包括右心衰10%、手术相关出血8%、心律失常8%和驱动线感染16%,无重大装置故障。
要点
- CH-VAD植入后1年、2年和3年生存率分别为93%、93%和89%。
- 主要不良事件为驱动线感染16%、右心衰10%、手术相关出血8%和心律失常8%。
- 主要血液相容性不良事件仅3例非致残性卒中和1例胃肠道出血,无重大装置故障。
核心结论
- 中国最大单中心CH-VAD经验显示高生存率和低并发症率,表明CH-VAD安全有效地为晚期心衰患者提供长期支持。
研究设计与样本
- 回顾性分析2017年6月至2023年8月阜外医院连续50例接受CH-VAD植入的患者临床数据。
主要发现
- 平均年龄47.9±13.9岁,男性90%,缺血性病因26%。
- INTERMACS profile 1为12%、2为56%、3为26%、4为6%。
- 平均支持时长868±630天(范围33天至6.4年)。
- Kaplan-Meier生存率1年93%(95%CI 79-98)、2年93%(95%CI 79-98)、3年89%(95%CI 71-96)。
- 40例(80%)仍在支持中,3例桥接至恢复,2例接受移植,5例在支持期间死亡。
关键数值与推荐
- 主要不良事件:右心衰10%、手术相关出血8%、心律失常8%、驱动线感染16%。
- 主要血液相容性不良事件仅3例非致残性卒中和1例胃肠道出血,随访期间无重大装置故障。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular assist devices (LVADs) are well-established for treating end-stage heart failure, but this therapy is only available to Chinese patients in recent years. The CH-VAD is the first used fully magnetically levitated pump in China. This study reports the long-term outcomes of a cohort supported by the CH-VAD for the first time. METHODS: From June 2017 to August 2023, 50 consecutive patients received CH-VAD implantation in Fuwai Hospital. Clinical data were collected and retrospectively analyzed. RESULTS: Baseline characteristics included a mean age of 47.9 ± 13.9 years, 90% male, and 26% ischemic etiology. The Interagency Registry for Mechanically Assisted Circulatory Support profile revealed 12% profile 1, 56% profile 2, 26% profile 3, and 6% profile 4. The mean support duration was 868 ± 630 days (range 33 days-6.4 years). Kaplan-Meier survival rate was 93% (95% CI, 79-98) at 1 year, 93% (95% CI, 79-98) at 2 years, and 89% (95% CI, 71-96) at 3 years. Forty patients (80%) currently remain on support, 3 were bridged to recovery, 2 received transplants, and 5 expired during support. Major adverse events (AEs) included right heart failure (10%), surgical-related bleeding (8%), arrhythmia (8%), and driveline infection (16%). Major hemocompatibility-related AEs were limited to 3 nondisabling strokes and 1 gastrointestinal bleeding. No major device malfunction occurred during the follow-up period. CONCLUSIONS: The largest single-center experience with the leading LVAD in China shows high survival with low complication rates, demonstrating that CH-VAD is safe and efficient in providing long-term support for patients with end-stage heart failure.
引用
- Wang X, Zhou X, Chen H, et al. Long-term outcomes of a novel fully magnetically levitated ventricular assist device for the treatment of advanced heart failure in China. J Heart Lung Transplant. 2024. PMID: 38740078. doi:10.1016/j.healun.2024.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。